Orgenesis Inc. (ORGS) is a biotech company that specializes in developing and manufacturing advanced therapies. The company focuses on technologies that enable the development, manufacturing, and delivery of personalized therapies for various medical conditions, including diabetes.
Orgenesis has two main business segments: POCare Therapeutics, which develops and commercializes personalized point-of-care cell and gene therapies, and Masthercell Global, which provides contract development and manufacturing services to the cell and gene therapy industry.
POCare Therapeutics is focused on developing breakthrough therapies for the treatment of diabetes, including the development of the company's flagship product, Autologous Insulin Producing (AIP) Cells. AIP Cells are personalized cell therapies designed to treat patients with severe Type 1 and Type 2 diabetes.
Masthercell Global is a leading contract development and manufacturing organization (CDMO) that provides clinical and commercial manufacturing services to cell and gene therapy companies. The company's services include process development, cGMP manufacturing, analytical testing, and regulatory support.
Orgenesis has partnerships and collaborations with academic institutions, research organizations, and biotech companies, and has a global presence with operations in the United States, Belgium, Germany, Israel, and South Korea.
As of February 18, 2023, Orgenesis Inc.'s market capitalization is approximately $197.4 million.
|
